Where do we come from? Is our destiny determined by the genes we inherit? Do we all see the same blue color when we look at the sky? In this book Gottfried (Jeff) Schatz, the world-renowned biochemist, gives lucid – albeit often surprising – answers to universal questions and takes the reader on a fascinating journey of discovery across the boundaries of scientific disciplines. With passion and a keen sense of wonder he draws on philosophy, cultural history and art to formulate his reflections on the mystery of life. The key to understanding life is to be found in its chemistry, and he proves that this is no dry endeavor and certainly not devoid of beauty. The result is a collection of eloquently and poetically written essays dealing with key issues in the natural sciences. It will appeal not only to scientists, but also to all inquisitive minds, regardless of educational and professional background.

"A collection of extraordinary essays, reminiscent in many ways – scope, erudition, clarity, occasional whimsicality and sassiness – of Stephen Jay Gould’s essays for *Natural History*"  
Herbert Deinert (Cornell University, Ithaca, N.Y.)

"A remarkable fusion of science and humanism"  
Eugene P. Kennedy (Harvard University, Boston, Mass.)
Guidelines for Authors

Submission
Before submission, please read the Guidelines for Authors for specific requirements for manuscript preparation. Manuscripts written in English are considered and should be submitted online at www.karger.com/che (a link leads you to the Submission Website).

Submission of an article implies author agreement with the below Conditions. To be considered for publication, all manuscripts must be accompanied by a cover letter signed by all authors stating that the work has not been published, nor is it under consideration elsewhere, and that all authors approve the submission.

A Copyright Transfer Form, available on the Submission Website, with the corresponding author's original (hand-written) signature must be received by the editorial office. Please print and sign the form, and upload it during submission (or fax or scan and email) to make it legally binding.

Authors should also state that animal experimentation was approved by an independent ethics committee. Copies of these guidelines and policy statements must be available for review by the editors if necessary.

Plagiarism Policy
Plagiarism or not plagiarism is a serious violation. Karger Publishers defines plagiarism as reproduction of another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Sections
Authors should indicate in the cover letter which manuscript type is being submitted for publication:

Original Papers: Fully documented reports of original research that must describe full sets of significant, original experiments in current anti-infective and antitumor chemotherapy research. Abstract, Introduction, Materials and Methods, Results, and Discussion sections are required. Consideration for publication is based on originality, novelty, scientific soundness, and appropriate analysis (maximum 3,000 words, 80 references, plus tables/figures).

Reviews: Comprehensive, state-of-the-art papers covering a timely topic by experts in the field (maximum 4,000 words, plus tables/figures, references). Reviews are usually invited by the Editor but may be unsolicited. Authors are asked to contact the Editor-in-Chief before submission in order to avoid clashes with other pending reviews. All review subjects are peer reviewed. An unstructured abstract of no more than 200 words is required.

Novel Insights from Clinical Practice: The journal only considers case reports that provide significant new insights into a clinical problem or with an extremely unusual clinical presentation. Manuscripts must contain all the text elements in the following order: title page, abstract and key words, main text, acknowledgments, references, table and figure legends. Tables and figures should be submitted as separate files according to the instructions below. Automatic line numbering should be used consecutively from the title page through to the final page. All pages should be numbered, starting from the title page, including tables, figure legends and figures.

Title Page: The first page should contain the concise title of the article along with a short title for use as a running head, the full names of the authors and their affiliations (department, institute, hospital, university etc. where the work was conducted). The full postal address, telephone and fax numbers, as well as the e-mail address of the author to whom correspondence should be sent must be given at the bottom of the title page.

Key words: Please supply 3–10 key words that reflect the content of the paper.

Abstract: Each original paper needs an abstract of up to 250 words structured with subheadings as follows: Background/Aims, Methods, Results, Conclusions. Structured abstracts are not needed for Reviews and Novel Insights from Clinical Practice.

Footnotes: Footnotes should be avoided. When essential, they should be numbered consecutively and appear at the foot of the appropriate page.

Acknowledgements: Include all sources of funding for the research presented in the manuscript and substantive contributions of individuals regarding the research or manuscript. All possible conflicts of interest should also be given here.

Abbreviations: Abbreviations (with the exception of those clearly well-established in the field) should be explained when they are first used.

Units of measurement: Measurements should be expressed in SI units wherever possible.

Drug names: Use generic names of drugs (first letter: lowercase) whenever possible. Registered trade names (first letter: uppercase) should be marked with the superscript registration symbol ® or ™ when they are first mentioned.

Tables and illustrations: Tables and figures must be numbered (e.g. Figure 1, Figure 2) and submitted as separate files. Tables require a heading and figures a legend, which may provide sufficient information for either to stand alone. Each figure and table must be cited in the text numerically. Tables should be in Word format. b/w half-tone and color figures must have a final resolution of 300 dpi after scaling to final size, line drawings 1,200 dpi. Color figures must be in RGB format. All figures should be in a common format such as PSD, TIF, PNG, EPS or WMF. Vector graphics should be in PPT, AI or EPS format.
**Color Illustrations**

**Online edition:** Color figures are reproduced free of charge. In the print version, the figures are reproduced in black and white. Referring to colors in the text and figure legends should be avoided.

**Print edition:** Up to 6 color figures per page can be integrated within the text at CHF 960.00 per page.

**References**

Identify references in the text using Arabic numerals (in square brackets). Do not alphabetize; number references sequentially in the order cited in the text. Material submitted for publication but not yet accepted should be referred to as [unpublished data] and should not be included in the reference list. The reference list should include only those publications which are cited in the text. Authors’ surnames should be followed by their initials with no punctuation other than a comma to separate individual authors. Preferably cite all authors (if not possible include at least 3 authors followed by et al). Abbreviate journal names according to the list of journals indexed for MEDLINE on the NLM website. Also see International Committee of Medical Journal Editors: Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.icmje.org).

**Examples**


**Reference Management Software:** The use of EndNote is recommended to facilitate formatting of citations and reference lists. The journal output style can be downloaded from http://endnote.com/downloads/styles.

**Supplementary Material and Multimedia Files**

Multimedia files and other supplementary files, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supplementary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modification or editing. Files should not exceed 10 Mb in size. Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. Additional supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://karger.figshare.com under a CC BY license. Authors will be charged a processing fee of CHF 250.00 for supplementary material.

**English Language Editing**

For authors whose native language is not English, use of a professional language editing service prior to submission can help to avoid delays with the review process.

**Digital Object Identifier (DOI)**

A DOI number will be available as a unique identifier on the title page of each article. DOIs are useful for identifying and citing articles published online without volume or issue information (for more information, see www.doi.org).

**Self-Archiving/Green Open Access**

Karger permits authors to archive their pre-prints (i.e. peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

- Be used for noncommercial purposes only
- Be linked to the final version on www.karger.com
- Include the following statement:

  “This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/doi- [insert DOI number].”

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article. Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf (see Funding Organizations (NIH etc.)).

For self-archiving Author’s Choice (Gold Open Access) articles, see Author’s Choice.

**Author’s Choice**

Karger’s Author’s Choice service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/author_choice. The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:

- Follow the terms of the relevant Creative Commons license
- Be linked to the final version on www.karger.com
- Include the following statement:

  “The final, published version of this article is available at http://www.karger.com/doi-[insert DOI number].”

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.
## General Information

**ISSN Print Edition:** 0009–3157  
**ISSN Online Edition:** 1421–9794

**Journal Homepage:** www.karger.com/che

**Publication Data:** Chemotherapy is published 6 times a year. Volume 62 with 6 issues appears in 2017.

**Copyright:** © 2017 S. Karger AG, Basel (Switzerland). All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

**Disclaimer:** The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

<table>
<thead>
<tr>
<th>Subscription Rates:</th>
<th>Back Volumes and Single Issues:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Print or Online</strong></td>
<td>Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at <a href="mailto:service@karger.com">service@karger.com</a>.</td>
</tr>
<tr>
<td>CHF 1232.00</td>
<td><strong>Print or Online combined</strong></td>
</tr>
<tr>
<td>EUR 1110.00</td>
<td>CHF 1282.00</td>
</tr>
<tr>
<td>USD 1339.00</td>
<td>EUR 1150.00</td>
</tr>
<tr>
<td><strong>postage and handling</strong></td>
<td>USD 1393.00</td>
</tr>
<tr>
<td>(added to print and print-online)</td>
<td>CHF 48.00 Europe, CHF 69.60 Overseas</td>
</tr>
<tr>
<td><strong>Print or Online</strong></td>
<td>EUR 43.20</td>
</tr>
<tr>
<td>CHF 2463.00</td>
<td>USD 84.00</td>
</tr>
<tr>
<td>EUR 2219.00</td>
<td><strong>Print or Online combined</strong></td>
</tr>
<tr>
<td>USD 2677.00</td>
<td>CHF 2832.00</td>
</tr>
<tr>
<td><strong>postage and handling</strong></td>
<td>EUR 2552.00</td>
</tr>
<tr>
<td>(added to print and print-online)</td>
<td>USD 3079.00</td>
</tr>
<tr>
<td><strong>Print or Online</strong></td>
<td>EUR 60.00 Europe, CHF 87.00 Overseas</td>
</tr>
<tr>
<td>CHF 69.60</td>
<td>EUR 54.00</td>
</tr>
</tbody>
</table>

**Subscription Orders:**  
Orders can be placed at agencies, bookstores, directly with the Publisher  
S. Karger AG  
Medical and Scientific Publishers  
Allschwilerstrasse 10  
CH–4009 Basel  
Switzerland  
t: +41 61 306 11 11  
f: +41 61 306 12 34  
e: karger@karger.com  
w: www.karger.com  
(for courier services only: Allschwilerstrasse 10 CH–4055 Basel)

**Change of Address:**  
Both old and new address should be sent to the subscription source.

**Photo of Paul Ehrlich on inner title page**  
Courtesy of the Paul-Ehrlich-Institute, Langen, Germany

---

Photo of Paul Ehrlich on inner title page  
Courtesy of the Paul-Ehrlich-Institute, Langen, Germany

---

**KARGER**  
© 2017 S. Karger AG, Basel

E-Mail karger@karger.com  
www.karger.com  
The Guidelines for Authors are available at:  
www.karger.com/che_Guidelines
Focusing on the special needs of AYA cancer patients

Tumors in Adolescents and Young Adults

Editors
Daniel P. Stark
Gilles Vassal

The field of adolescents and young adults (AYA) oncology is experiencing a very challenging time. This book is a guide to the key issues for any clinician and health professional managing AYA with cancer in Europe. Emphasis is on collaboration between adult and pediatric specialists. Authors present their perception of the current state of the most prominent primary issues in AYA oncology.

Chapters cover cross-cutting issues such as disease epidemiology, systems of care, access to innovative therapy and late effects of treatment and survivorship for AYA-onset cancers. There are discussions of the latest developments and the most important cancer types in AYA, including the shared perspectives of adult and pediatric specialists. Throughout the book recurrent challenges to the AYA community are exposed and solutions proposed.

Tumors in Adolescents and Young Adults is highly recommended to any oncologist or hematologist treating patients aged 15 to 39 diagnosed with cancer. It will also be of interest to other members of the multidisciplinary teams involved with this patient group.

Contents
Preface: Stark, D.P.; Vassal, G.

Cross-Cutting Issues
- Epidemiology of Adolescents and Young Adults with Cancer in Europe: Desandes, E.; Stark, D.P.
- Supportive Care: Olsen, P.R.; Lorenzo, R.
- Long-Term Follow-Up and Survivorship: Tsirou, A.; Hjorth, L.
- Increasing Access to Clinical Trials and Innovative Therapy for Teenagers and Young Adults with Cancer – A Multiple Stakeholders and Multiple Steps Process: Gaspar, N.; Fern, L.
- Collaboration and Networking: Husson, O.; Manten-Horst, E.; van der Graaf, W.T.A.

Specific Illnesses
- Adult Cancers in Adolescents and Young Adults: Laurence, V.; Marples, M.; Stark, D.P.
- Pediatric Cancers and Brain Tumors in Adolescents and Young Adults: McCabe, M.G.; Valteau-Couanet, D.
- Leukemia: Juliusson, G.; Hough, R.
- Lymphoma in Adolescents and Young Adults: Brugières, L.; Brice, P.
- Germ Cell Tumors in Adolescents and Young Adults: Calaminus, G.; Joffe, J.
- Sarcomas of Soft Tissue and Bone: Ferrari, A.; Dirksen, U.; Bielack, S.

Author Index
Subject Index

The easiest way to order: www.karger.com/pritr

Dear Librarian
I have reviewed this publication and would like to recommend it for our library.

Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

KARGER
Issues in Infectious Diseases

Infections are a constant threat to human health. Over the last two decades a number of new infective agents such as HIV and prions have been identified, and several infectious diseases previously considered under control have suddenly reemerged. The problem of infection is aggravated by the resistance of many microorganisms to currently available antimicrobials and by the growing number of immuno-compromised people worldwide. The steadily rising incidence of nosocomial infections is a further cause for concern.

This series presents original data and reviews the latest clinical information on infectious diseases of bacterial, viral, fungal and parasitic origin. Covering epidemiology, pathogenesis, prevention and treatment, it also considers the latest diagnostic techniques, evaluates new antimicrobial drugs and reports recent advances in vaccine development. As infections involve almost all branches of medicine, books published in this series represent a valuable source of information for a wide spectrum of clinicians and health care professionals.

Monographs in Virology

Compact and thorough reference volumes for virologists and non-virologists alike

A skilful selection of topics of exceptional importance and a panel of acknowledged experts as authors have ensured an outstanding reputation for this series. Each monograph, centered on an active area of virologic research, provides a critical evaluation of recent progress and a useful commentary on the direction of future research. Characterized by a consistently high standard of scholarship and clear presentation of content, volumes in this series have proved their enduring value as convenient reference tools for both virologists working in the field and scientists working in allied areas.

Monographs in Virology

**Vol. 7: Chlamydial Infection: A Clinical and Public Health Perspective**

**Vol. 6: Antimicrobial Resistance**

**Vol. 5: Wolbachia: A Bug’s Life in another Bug**

**Vol. 4: Emerging Viral Diseases of Southeast Asia**

**Vol. 3: An Emerging Viral Disease: A Bug’s Life in another Bug**

**Vol. 2: Viral Hepatitis**

**Vol. 1: Models of Viral Hepatitis**

A skilful selection of topics of exceptional importance and a panel of acknowledged experts as authors have ensured an outstanding reputation for this series. Each monograph, centered on an active area of virologic research, provides a critical evaluation of recent progress and a useful commentary on the direction of future research. Characterized by a consistently high standard of scholarship and clear presentation of content, volumes in this series have proved their enduring value as convenient reference tools for both virologists working in the field and scientists working in allied areas.
Contents

See the journal website for contents
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
Antimicrobial Section

Original Papers

94 Determination of the Mutant Prevention Concentration and the Mutant Selection Window of Topical Antimicrobial Agents against Propionibacterium acnes
Nakase, K.; Nakaminami, H.; Toda, Y.; Noguchi, N. (Tokyo)

105 In vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in Combination against Multidrug-Resistant Pseudomonas aeruginosa

121 Adaptive Cross-Resistance to Aminoglycoside Antibiotics in Pseudomonas aeruginosa Induced by Topical Dosage of Neomycin

128 Biofilm Formation Restrained by Subinhibitory Concentrations of Tigecyclin in Acinetobacter baumannii Is Associated with Downregulation of Efflux Pumps

Short Communication

100 Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes
Giancola, S.E.; Mahoney, M.V.; Hogan, M.D.; Raux, B.R.; McCoy, C.; Hirsch, E.B. (Boston, MA)

Anticancer Section

Review

111 Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions
Musella, A.; Vertechy, L.; Romito, A.; Marchetti, C.; Giannini, A.; Sciuga, V.; Bracchi, C.; Tomao, F.; Di Donato, V.; De Felice, F.; Monti, M.; Muzii, L.; Benedetti Panici, P. (Rome)

Original Papers

85 Lysosome Inhibitors Enhance the Chemotherapeutic Activity of Doxorubicin in HepG2 Cells
Li, Y.; Sun, Y.; Jing, L.; Wang, J.; Yan, Y.; Feng, Y.; Zhang, Y.; Liu, Z.; Ma, L.; Dao, A. (Tianjin)

134 A Difference in the Incidences of Hypersensitivity Reactions to Original and Generic Taxanes
Ratanajarusiri, T.; Sriuranpong, V.; Sitthideatphaiboon, P.; Poovoravan, N.; Vinayanuwat, C.; Parinyanitikul, N.; Angspatt, P.; Thawinwisan, W.; Tanasanvimon, S. (Bangkok)

Novel Insights from Clinical Practice

140 Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20%
Alrifai, T.; Grant Szymanski, K.; Venugopal, P.; Mahon, B.; Okwuosa, T.; Karmali, R. (Chicago, IL)